Is ForceField Energy (FNRG) Under Short Selling Attack?
Post# of 67
Posted On: 04/18/2015 8:31:10 PM
Shares of ForceField Energy Inc. (FNRG) touched the $3.66 mark on Friday, representing the lowest intraday price the stock has reached over the past 52 weeks.
FNRG requested that a regulatory agency review the trading activity in its common stock subsequent to the issuance of a lengthy "opinion" published by MoxReports on April 15, 2015; in addition to any relationships, arrangements and commonalities between short sellers and others.
FNRG said that the opinion was written by an individual investor, not a registered financial advisor, who has disclosed owning a short position in FNRG common stock.
According to FNRG, the article contains material inaccuracies about its management, business and prospects, and appears to be an orchestrated short selling attack based on misinformation.
FNRG will provide its shareholders and investment community a business update in a release pre-market on Monday, April 20, 2015.
FNRG finished the trading session at $3.97 per share, down $0.77 (or -16.24%).
FNRG and its subsidiaries comprise a global company whose products and solutions focus on sustainable energy solutions and improved energy efficiency.
More about ForceField Energy Inc. (FNRG) at www.forcefieldenergy.com
**
After the closing bell on Friday, Baxter International Inc. (BAX) said that the Phase III clinical trial of BAX 111 met its primary efficacy endpoint, defined by the number of patients with severe von Willebrand disease who achieved treatment success for control of bleeding episodes.
The trial was designed to assess the safety, efficacy and pharmacokinetics of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.
These positive data support the application BAX submitted to the United States Food and Drug Administration (FDA) in late 2014 for approval of BAX 111. Both the European Commission and the FDA have granted orphan-drug designation for BAX 111.
BAX, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
More about Baxter International Inc. (BAX) at www.baxter.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Nipomo, CA ( www.nipomo.crwe-pr.com ) into the CRWE Network.
Nipomo is the most populated unincorporated area in San Luis Obispo County, California. Agriculture continues to be the dominant business in Nipomo.
Nipomo had an estimated population in 2010 (U.S. Census Bureau) of 16,714, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
FNRG requested that a regulatory agency review the trading activity in its common stock subsequent to the issuance of a lengthy "opinion" published by MoxReports on April 15, 2015; in addition to any relationships, arrangements and commonalities between short sellers and others.
FNRG said that the opinion was written by an individual investor, not a registered financial advisor, who has disclosed owning a short position in FNRG common stock.
According to FNRG, the article contains material inaccuracies about its management, business and prospects, and appears to be an orchestrated short selling attack based on misinformation.
FNRG will provide its shareholders and investment community a business update in a release pre-market on Monday, April 20, 2015.
FNRG finished the trading session at $3.97 per share, down $0.77 (or -16.24%).
FNRG and its subsidiaries comprise a global company whose products and solutions focus on sustainable energy solutions and improved energy efficiency.
More about ForceField Energy Inc. (FNRG) at www.forcefieldenergy.com
**
After the closing bell on Friday, Baxter International Inc. (BAX) said that the Phase III clinical trial of BAX 111 met its primary efficacy endpoint, defined by the number of patients with severe von Willebrand disease who achieved treatment success for control of bleeding episodes.
The trial was designed to assess the safety, efficacy and pharmacokinetics of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.
These positive data support the application BAX submitted to the United States Food and Drug Administration (FDA) in late 2014 for approval of BAX 111. Both the European Commission and the FDA have granted orphan-drug designation for BAX 111.
BAX, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions.
More about Baxter International Inc. (BAX) at www.baxter.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Nipomo, CA ( www.nipomo.crwe-pr.com ) into the CRWE Network.
Nipomo is the most populated unincorporated area in San Luis Obispo County, California. Agriculture continues to be the dominant business in Nipomo.
Nipomo had an estimated population in 2010 (U.S. Census Bureau) of 16,714, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE Network. It will allow people to submit their listings for exposure to visitors searching for homes.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)ForceField Energy Inc. (FNRG) Stock Research Links
Scroll down for more posts ▼